Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …

Inflammation, especially chronic inflammation, plays a pivotal role in tumorigenesis and
metastasis through various mechanisms and is now recognized as a hallmark of cancer and …

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Compared with conventional chemotherapy and targeted therapy, immunotherapy has
changed the treatment prospects of various solid tumors and has recently become the main …

Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …

Background Based on recent research reports, dysbiosis and improper concentrations of
microbial metabolites in the gut may result into the carcinogenesis of colorectal cancer …

Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1
(PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers …

Objective To explore the efficacy and safety of single-agent programmed cell death protein-1
(PD-1) inhibitor in the neoadjuvant treatment of patients with mismatch repair-deficient …

Colorectal cancer (CRC) is considered as the second most common cancer worldwide. For
the past few years, the role of immunotherapy has been extensively studied and it has been …

Background Immunotherapy for colorectal cancer has developed rapidly in the past decade.
Many high-quality clinical trials examining the application of PD-1/PD-L1 inhibitors in …